Invention Grant
- Patent Title: Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
-
Application No.: US15399122Application Date: 2017-01-05
-
Publication No.: US10596257B2Publication Date: 2020-03-24
- Inventor: Marina Bacac , Sara Colombetti , Christian Klein , Johannes Sam , Jose Saro , Pablo Umana
- Applicant: Hoffmann-La Roche Inc.
- Applicant Address: US NJ Little Falls
- Assignee: Hoffmann-La Roche Inc.
- Current Assignee: Hoffmann-La Roche Inc.
- Current Assignee Address: US NJ Little Falls
- Agency: Clark & Elbing LLP
- Agent Karen L. Elbing
- Priority: EP16150506 20160108
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K39/00
Abstract:
The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
Public/Granted literature
Information query
